骨系統疾患治療薬の世界市場調査レポート：産業分析、規模、シェア、成長、動向、2024年から2032年までの予測

骨系統疾患治療薬の世界需要は、2023年の34億5,000万米ドルから2032年には52億2,000万米ドル近くの市場規模に達すると推定され、調査期間2024-2032年のCAGRは4.71%です。

骨系統疾患治療薬は、骨の成長と発育の異常を特徴とする遺伝性疾患群である骨系統疾患の治療に使用される医薬品です。これらの薬剤は、骨形成異常、成長板機能不全、骨格変形を含む骨系統疾患の基礎となる病態生理の様々な側面を標的とし、罹患者の骨の健康、成長、QOLを改善します。これらの薬剤には、成長ホルモン療法、骨修飾剤、酵素補充療法、および様々なタイプの骨系統疾患に関連する特定の分子または細胞の欠陥に対処するようにデザインされた他の標的療法が含まれます。治療戦略は、遺伝子変異、臨床症状、個々の患者のニーズによって異なります。

市場力学

遺伝子研究および分子診断学の進歩により、骨格形成不全に関連する新規遺伝子変異の同定が可能となり、疾患メカニズムの理解が深まり、標的薬剤開発の取り組みが促進されます。研究者が骨系統疾患の遺伝的背景を解明するにつれ、潜在的な治療標的や骨成長、軟骨形成、骨格開発を調節する薬剤候補のパイプラインが増加しています。さらに、製薬会社、学術機関、患者支援団体間の協力により、骨系統疾患に対する安全かつ効果的な治療法の開発に焦点を当てた研究イニシアチブと臨床試験が推進され、骨系統疾患治療薬市場の成長を牽引しています。さらに、希少疾病用医薬品の指定や早期承認のような規制上の優遇措置は、医薬品の開発と商業化を促進し、骨系統疾患治療薬市場への投資を促進しています。

さらに、アンメットメディカルニーズと骨系統疾患の患者や家族への負担に対する認識の高まりは、この分野におけるアドボカシー活動や研究開発への資金援助を後押ししています。ドラッグデリバリー技術と個別化医療アプローチの進歩は、骨系統疾患患者の治療成績と生活の質を改善する新たな機会を提供します。しかしながら、骨系統疾患のメカニズムに対する理解は限られており、希少疾患に対する薬剤開発の課題は、今後数年間の骨系統疾患治療薬市場の成長に影響を与える可能性があります。

調査レポートは、ポーターのファイブフォースモデル、市場の魅力分析、バリューチェーン分析をカバーしています。これらのツールは、業界の構造を明確に把握し、世界レベルでの競合の魅力を評価するのに役立ちます。さらに、これらのツールは骨系統疾患治療薬の世界市場における各セグメントを包括的に評価することもできます。骨系統疾患治療薬産業の成長と動向は、この調査に全体的なアプローチを提供します。

市場セグメンテーション

骨系統疾患治療薬市場レポートのこのセクションでは、国別および地域別のセグメントに関する詳細なデータを提供し、戦略担当者がそれぞれの製品またはサービスのターゲット層を特定する上で、今後のビジネスチャンスを支援します。

異形成タイプ別

• モルキオA症候群
• X連鎖性低リン血症
• 低リン血症
• 軟骨無形成症
• 進行性骨化性線維異形成症
• 多発性骨軟骨腫
• その他

治療別

• 酵素補充療法
• ヒトモノクローナル抗体
• その他

流通チャネル別

• 病院薬局
• 小売薬局
• オンライン薬局

地域別分析

本セクションでは、北米、欧州、アジア太平洋、ラテンアメリカ、中東＆アフリカにおける骨系統疾患治療薬市場の現在および将来の需要を強調する地域展望をカバーします。さらに、本レポートは、すべての主要地域における個々のアプリケーションセグメントの需要、推定・予測に焦点を当てています。

カスタム要件がある場合は、お問い合わせください。当社の調査チームは、お客様のニーズに応じてカスタマイズしたレポートを提供することができます。

目次

第1章 序文

第2章 エグゼクティブサマリー

• 市場のハイライト
• 世界市場スナップショット

第3章 骨系統疾患治療薬- 産業分析

• イントロダクション：市場力学
• 市場促進要因
• 市場抑制要因
• 市場機会
• 業界動向
• ポーターのファイブフォース分析
• 市場の魅力分析

第4章 バリューチェーン分析

• バリューチェーン分析
• 原材料分析
  • 原材料リスト
  • 原材料メーカーリスト
  • 主要原材料の価格動向
• 潜在的バイヤーのリスト
• マーケティングチャネル
  • ダイレクトマーケティング
  • インダイレクトマーケティング
  • マーケティングチャネル発展動向

第5章 骨系統疾患治療薬の世界市場分析：異形成タイプ別

• 概要：異形成タイプ別
• 実績・予測データ分析：異形成タイプ別
• モルキオA症候群
• X連鎖性低リン血症
• 低リン血症
• 軟骨無形成症
• 進行性骨化性線維異形成症
• 多発性骨軟骨腫
• その他

第6章 骨系統疾患治療薬の世界市場分析：治療別

• 概要：治療別
• 実績・予測データ分析：治療別
• 酵素補充療法
• ヒトモノクローナル抗体
• その他

第7章 骨系統疾患治療薬の世界市場分析：流通チャネル別

• 概要：流通チャネル別
• 実績・予測データ分析：流通チャネル別
• 病院薬局
• 小売薬局
• オンライン薬局

第8章 骨系統疾患治療薬の世界市場分析：地域別

• 地域別展望
• イントロダクション
• 北米の売上分析
  • 概要、実績と予測
  • 北米：セグメント別
  • 北米：国別
  • 米国
  • カナダ
  • メキシコ
• 欧州の売上分析
  • 概要、実績と予測
  • 欧州：セグメント別
  • 欧州：国別
  • 英国
  • フランス
  • ドイツ
  • イタリア
  • ロシア
  • その他欧州
• アジア太平洋地域の売上分析
  • 概要、実績と予測
  • アジア太平洋地域：セグメント別
  • アジア太平洋地域：国別
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア
  • 東南アジア
  • その他アジア太平洋地域
• ラテンアメリカの売上分析
  • 概要、実績と予測
  • ラテンアメリカ：セグメント別
  • ラテンアメリカ：国別
  • ブラジル
  • アルゼンチン
  • ペルー
  • チリ
  • その他ラテンアメリカ
• 中東・アフリカの売上分析
  • 概要、実績と予測
  • 中東・アフリカ：セグメント別
  • 中東・アフリカ：国別
  • サウジアラビア
  • アラブ首長国連邦
  • イスラエル
  • 南アフリカ
  • その他中東・アフリカ

第9章 骨系統疾患治療薬企業の競合情勢

• 骨系統疾患治療薬の市場競争
• 提携・協力・協定
• 合併・買収
• 新製品上市
• その他の開発

第10章 企業プロファイル

• 上位企業の市場シェア分析
• 市場集中度
• AbbVie Inc.
• Alexion Pharmaceuticals Inc.
• Amgen Inc.
• BioMarin Pharmaceutical Inc.
• Horizon Therapeutics Plc
• Johnson & Johnson
• Mallinckrodt Pharmaceuticals
• Novartis AG
• Pfizer Inc.
• Regeneron Pharmaceuticals Inc.
• Sanofi
• Sarepta Therapeutics Inc.
• Takeda Pharmaceutical Company Limited
• Ultragenyx Pharmaceutical Inc.
• Vertex Pharmaceuticals Incorporated

LIST OF TABLES

• Market Snapshot
• Drivers: Impact Analysis
• Restraints: Impact Analysis
• List of Raw Material
• List of Raw Material Manufactures
• Analysis By Dysplasia Type (USD MN)
• Morquio A Syndrome Market Sales By Geography (USD MN)
• X-Linked Hypophosphatemia Market Sales By Geography (USD MN)
• Hypophosphatasia Market Sales By Geography (USD MN)
• Achondroplasia Market Sales By Geography (USD MN)
• Fibrodysplasia Ossificans Progressive Market Sales By Geography (USD MN)
• Multiple Osteochondromas Market Sales By Geography (USD MN)
• Other Market Sales By Geography (USD MN)
• Analysis By Treatment (USD MN)
• Enzyme Replacement Therapy Market Sales By Geography (USD MN)
• Human Monoclonal Antibody Market Sales By Geography (USD MN)
• Other Market Sales By Geography (USD MN)
• Analysis By Distribution Channel (USD MN)
• Hospital Pharmacies Market Sales By Geography (USD MN)
• Retail Pharmacies Market Sales By Geography (USD MN)
• Online Pharmacies Market Sales By Geography (USD MN)
• Global Skeletal Dysplasia Drugs Market Sales By Geography (USD MN)
• North America Market Analysis (USD MN)
• United States Market Analysis (USD MN)
• Canada Market Analysis (USD MN)
• Mexico Market Analysis (USD MN)
• Europe Market Analysis (USD MN)
• Europe Market Estimate By Country (USD MN)
• United Kingdom Market Analysis (USD MN)
• France Market Analysis (USD MN)
• Germany Market Analysis (USD MN)
• Italy Market Analysis (USD MN)
• Russia Market Analysis (USD MN)
• Spain Market Analysis (USD MN)
• Rest of Europe Market Analysis (USD MN)
• Asia Pacific Market Analysis (USD MN)
• China Market Analysis (USD MN)
• Japan Market Analysis (USD MN)
• India Market Analysis (USD MN)
• South Korea Market Analysis (USD MN)
• Australia Market Analysis (USD MN)
• South East Asia Market Analysis (USD MN)
• Rest of Asia Pacific Market Analysis (USD MN)
• Latin America Market Analysis (USD MN)
• Brazil Market Analysis (USD MN)
• Argentina Market Analysis (USD MN)
• Peru Market Analysis (USD MN)
• Chile Market Analysis (USD MN)
• Rest of Latin America Market Analysis (USD MN)
• Middle East & Africa Market Analysis (USD MN)
• Saudi Arabia Market Analysis (USD MN)
• UAE Market Analysis (USD MN)
• Israel Market Analysis (USD MN)
• South Africa Market Analysis (USD MN)
• Rest of Middle East and Africa Market Analysis (USD MN)
• Partnership/Collaboration/Agreement
• Mergers And Acquisition

LIST OF FIGURES

• Research Scope of Skeletal Dysplasia Drugs Report
• Market Research Process
• Market Research Methodology
• Global Skeletal Dysplasia Drugs Market Size, By Region (USD MN)
• Porters Five Forces Analysis
• Market Attractiveness Analysis By Dysplasia Type
• Market Attractiveness Analysis By Treatment
• Market Attractiveness Analysis By Distribution Channel
• Market Attractiveness Analysis By Region
• Value Chain Analysis
• Global Market Analysis By Dysplasia Type (USD MN)
• Morquio A Syndrome Market Sales By Geography (USD MN)
• X-Linked Hypophosphatemia Market Sales By Geography (USD MN)
• Hypophosphatasia Market Sales By Geography (USD MN)
• Achondroplasia Market Sales By Geography (USD MN)
• Fibrodysplasia Ossificans Progressive Market Sales By Geography (USD MN)
• Multiple Osteochondromas Market Sales By Geography (USD MN)
• Other Market Sales By Geography (USD MN)
• Global Market Analysis By Treatment (USD MN)
• Enzyme Replacement Therapy Market Sales By Geography (USD MN)
• Human Monoclonal Antibody Market Sales By Geography (USD MN)
• Other Market Sales By Geography (USD MN)
• Global Market Analysis By Distribution Channel (USD MN)
• Hospital Pharmacies Market Sales By Geography (USD MN)
• Retail Pharmacies Market Sales By Geography (USD MN)
• Online Pharmacies Market Sales By Geography (USD MN)
• Global Market Sales (USD MN)
• North America Market Sales (USD MN)
• Europe Market Sales (USD MN)
• Asia Pacific Market Sales (USD MN)
• Latin America Market Sales (USD MN)
• Middle East & Africa Market Sales (USD MN)
• Recent Development in Industry
• Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.

The global demand for Skeletal Dysplasia Drugs Market is presumed to reach the market size of nearly USD 5.22 Billion by 2032 from USD 3.45 Billion in 2023 with a CAGR of 4.71% under the study period 2024-2032.

Skeletal dysplasia drugs are pharmaceutical agents used in treating skeletal dysplasias, a group of genetic disorders characterized by abnormalities in bone growth and development. These drugs target various aspects of the underlying pathophysiology of skeletal dysplasias, including abnormal bone formation, growth plate dysfunction, and skeletal deformities, to improve bone health, growth, and quality of life in affected individuals. These drugs may include growth hormone therapy, bone-modifying agents, enzyme replacement therapy, and other targeted therapies designed to address specific molecular or cellular defects associated with different types of skeletal dysplasias. Treatment strategies may vary depending on genetic mutation, clinical manifestations, and individual patient needs.

MARKET DYNAMICS

Advancements in genetic research and molecular diagnostics enable the identification of novel genetic mutations concerned with skeletal dysplasias, enhancing our understanding of disease mechanisms and facilitating targeted drug development efforts. As researchers unravel the genetic underpinnings of skeletal dysplasias, there's a growing pipeline of potential therapeutic targets and drug candidates to modulate bone growth, cartilage formation, and skeletal development. Additionally, collaborations between pharmaceutical companies, academic institutions, and patient advocacy groups drive research initiatives and clinical trials focused on developing safe & effective treatments for skeletal dysplasias, driving skeletal dysplasia drug market growth. Moreover, regulatory incentives such as orphan drug designations and accelerated approval pathways expedite the development and commercialization of drugs, incentivizing investment in the skeletal dysplasia drugs market.

Furthermore, the growing recognition of the unmet medical needs and the burden of skeletal dysplasias on patients and families drive advocacy efforts and funding support for research and drug development in this field. Advancements in drug delivery technologies and personalized medicine approaches offer new opportunities to improve treatment outcomes and quality of life for individuals with skeletal dysplasias. However, a limited understanding of skeletal dysplasia mechanisms and challenges in drug development for rare diseases may challenge the skeletal dysplasia drug market growth in the coming years.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Skeletal Dysplasia Drugs. The growth and trends of Skeletal Dysplasia Drugs industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Skeletal Dysplasia Drugs market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Dysplasia Type

• Morquio A Syndrome
• X-Linked Hypophosphatemia
• Hypophosphatasia
• Achondroplasia
• Fibrodysplasia Ossificans Progressive
• Multiple Osteochondromas
• Other

By Treatment

• Enzyme Replacement Therapy
• Human Monoclonal Antibody
• Other

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Skeletal Dysplasia Drugs market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Skeletal Dysplasia Drugs market include AbbVie Inc., Alexion Pharmaceuticals Inc., Amgen Inc., BioMarin Pharmaceutical Inc., Horizon Therapeutics Plc, Johnson & Johnson, Mallinckrodt Pharmaceuticals, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi, Sarepta Therapeutics Inc., Takeda Pharmaceutical Company Limited, Ultragenyx Pharmaceutical Inc., Vertex Pharmaceuticals Incorporated. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

• 1.1. Report Description
  • 1.1.1 Objective
  • 1.1.2 Target Audience
  • 1.1.3 Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1 Market Research Process
  • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3. SKELETAL DYSPLASIA DRUGS - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Dysplasia Type
  • 3.7.2 Market Attractiveness Analysis By Treatment
  • 3.7.3 Market Attractiveness Analysis By Distribution Channel
  • 3.7.4 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1 List of Raw Materials
  • 4.2.2 Raw Material Manufactures List
  • 4.2.3 Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1 Direct Marketing
  • 4.4.2 Indirect Marketing
  • 4.4.3 Marketing Channel Development Trend

5. GLOBAL SKELETAL DYSPLASIA DRUGS MARKET ANALYSIS BY DYSPLASIA TYPE

• 5.1. Overview By Dysplasia Type
• 5.2. Historical and Forecast Data Analysis By Dysplasia Type
• 5.3. Morquio A Syndrome Historic and Forecast Sales By Regions
• 5.4. X-Linked Hypophosphatemia Historic and Forecast Sales By Regions
• 5.5. Hypophosphatasia Historic and Forecast Sales By Regions
• 5.6. Achondroplasia Historic and Forecast Sales By Regions
• 5.7. Fibrodysplasia Ossificans Progressive Historic and Forecast Sales By Regions
• 5.8. Multiple Osteochondromas Historic and Forecast Sales By Regions
• 5.9. Other Historic and Forecast Sales By Regions

6. GLOBAL SKELETAL DYSPLASIA DRUGS MARKET ANALYSIS BY TREATMENT

• 6.1. Overview By Treatment
• 6.2. Historical and Forecast Data Analysis By Treatment
• 6.3. Enzyme Replacement Therapy Historic and Forecast Sales By Regions
• 6.4. Human Monoclonal Antibody Historic and Forecast Sales By Regions
• 6.5. Other Historic and Forecast Sales By Regions

7. GLOBAL SKELETAL DYSPLASIA DRUGS MARKET ANALYSIS BY DISTRIBUTION CHANNEL

• 7.1. Overview By Distribution Channel
• 7.2. Historical and Forecast Data Analysis By Distribution Channel
• 7.3. Hospital Pharmacies Historic and Forecast Sales By Regions
• 7.4. Retail Pharmacies Historic and Forecast Sales By Regions
• 7.5. Online Pharmacies Historic and Forecast Sales By Regions

8. GLOBAL SKELETAL DYSPLASIA DRUGS MARKET ANALYSIS BY GEOGRAPHY

• 8.1. Regional Outlook
• 8.2. Introduction
• 8.3. North America Sales Analysis
  • 8.3.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.3.2 North America By Segment Sales Analysis
  • 8.3.3 North America By Country Sales Analysis
  • 8.3.4 United States Sales Analysis
  • 8.3.5 Canada Sales Analysis
  • 8.3.6 Mexico Sales Analysis
• 8.4. Europe Sales Analysis
  • 8.4.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.4.2 Europe By Segment Sales Analysis
  • 8.4.3 Europe By Country Sales Analysis
  • 8.4.4 United Kingdom Sales Analysis
  • 8.4.5 France Sales Analysis
  • 8.4.6 Germany Sales Analysis
  • 8.4.7 Italy Sales Analysis
  • 8.4.8 Russia Sales Analysis
  • 8.4.9 Rest Of Europe Sales Analysis
• 8.5. Asia Pacific Sales Analysis
  • 8.5.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.5.2 Asia Pacific By Segment Sales Analysis
  • 8.5.3 Asia Pacific By Country Sales Analysis
  • 8.5.4 China Sales Analysis
  • 8.5.5 India Sales Analysis
  • 8.5.6 Japan Sales Analysis
  • 8.5.7 South Korea Sales Analysis
  • 8.5.8 Australia Sales Analysis
  • 8.5.9 South East Asia Sales Analysis
  • 8.5.10 Rest Of Asia Pacific Sales Analysis
• 8.6. Latin America Sales Analysis
  • 8.6.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.6.2 Latin America By Segment Sales Analysis
  • 8.6.3 Latin America By Country Sales Analysis
  • 8.6.4 Brazil Sales Analysis
  • 8.6.5 Argentina Sales Analysis
  • 8.6.6 Peru Sales Analysis
  • 8.6.7 Chile Sales Analysis
  • 8.6.8 Rest of Latin America Sales Analysis
• 8.7. Middle East & Africa Sales Analysis
  • 8.7.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.7.2 Middle East & Africa By Segment Sales Analysis
  • 8.7.3 Middle East & Africa By Country Sales Analysis
  • 8.7.4 Saudi Arabia Sales Analysis
  • 8.7.5 UAE Sales Analysis
  • 8.7.6 Israel Sales Analysis
  • 8.7.7 South Africa Sales Analysis
  • 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE SKELETAL DYSPLASIA DRUGS COMPANIES

• 9.1. Skeletal Dysplasia Drugs Market Competition
• 9.2. Partnership/Collaboration/Agreement
• 9.3. Merger And Acquisitions
• 9.4. New Product Launch
• 9.5. Other Developments

10. COMPANY PROFILES OF SKELETAL DYSPLASIA DRUGS INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Market Concentration Rate
• 10.3. AbbVie Inc.
  • 10.3.1 Company Overview
  • 10.3.2 Company Revenue
  • 10.3.3 Products
  • 10.3.4 Recent Developments
• 10.4. Alexion Pharmaceuticals Inc.
  • 10.4.1 Company Overview
  • 10.4.2 Company Revenue
  • 10.4.3 Products
  • 10.4.4 Recent Developments
• 10.5. Amgen Inc.
  • 10.5.1 Company Overview
  • 10.5.2 Company Revenue
  • 10.5.3 Products
  • 10.5.4 Recent Developments
• 10.6. BioMarin Pharmaceutical Inc.
  • 10.6.1 Company Overview
  • 10.6.2 Company Revenue
  • 10.6.3 Products
  • 10.6.4 Recent Developments
• 10.7. Horizon Therapeutics Plc
  • 10.7.1 Company Overview
  • 10.7.2 Company Revenue
  • 10.7.3 Products
  • 10.7.4 Recent Developments
• 10.8. Johnson & Johnson
  • 10.8.1 Company Overview
  • 10.8.2 Company Revenue
  • 10.8.3 Products
  • 10.8.4 Recent Developments
• 10.9. Mallinckrodt Pharmaceuticals
  • 10.9.1 Company Overview
  • 10.9.2 Company Revenue
  • 10.9.3 Products
  • 10.9.4 Recent Developments
• 10.10. Novartis AG
  • 10.10.1 Company Overview
  • 10.10.2 Company Revenue
  • 10.10.3 Products
  • 10.10.4 Recent Developments
• 10.11. Pfizer Inc.
  • 10.11.1 Company Overview
  • 10.11.2 Company Revenue
  • 10.11.3 Products
  • 10.11.4 Recent Developments
• 10.12. Regeneron Pharmaceuticals Inc.
  • 10.12.1 Company Overview
  • 10.12.2 Company Revenue
  • 10.12.3 Products
  • 10.12.4 Recent Developments
• 10.13. Sanofi
  • 10.13.1 Company Overview
  • 10.13.2 Company Revenue
  • 10.13.3 Products
  • 10.13.4 Recent Developments
• 10.14. Sarepta Therapeutics Inc.
  • 10.14.1 Company Overview
  • 10.14.2 Company Revenue
  • 10.14.3 Products
  • 10.14.4 Recent Developments
• 10.15. Takeda Pharmaceutical Company Limited
  • 10.15.1 Company Overview
  • 10.15.2 Company Revenue
  • 10.15.3 Products
  • 10.15.4 Recent Developments
• 10.16. Ultragenyx Pharmaceutical Inc.
  • 10.16.1 Company Overview
  • 10.16.2 Company Revenue
  • 10.16.3 Products
  • 10.16.4 Recent Developments
• 10.17. Vertex Pharmaceuticals Incorporated
  • 10.17.1 Company Overview
  • 10.17.2 Company Revenue
  • 10.17.3 Products
  • 10.17.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies